AgingResearch.NewsJoin free

Denali Therapeutics

CompanyUnited StatesFounded 2015

Wikidata

Denali Therapeutics develops 3 assets, the furthest in phase 2 (BIIB122 in LRRK2 Parkinson's disease). Mostly protein or enzyme and small molecule acting on proteostasis, autophagy and LRRK2; based in the United States, founded in 2015.

3
Assets
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

3

  • BIIB122

    Small-molecule LRRK2 kinase inhibitor

    Phase 2, Small molecule, Autophagy, LRRK2, LRRK2 Parkinson's disease

  • DNL593

    Blood-brain-barrier-crossing progranulin replacement protein

    Phase 1, Protein or enzyme, Proteostasis, GRN, frontotemporal dementia

  • Zafinofusp alfa

    Blood-brain-barrier-crossing SGSH enzyme replacement protein

    Phase 1, Protein or enzyme, Proteostasis, SGSH, Sanfilippo syndrome type a

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Similar companies6

Intelligence